This paper aims to synthesize literature about the defnition, prevalence, onset and treatments associated with late effects. A rapid review was conducted using Google Scholar to identify reviews related to the late effects of adult-onset cancers. Papers were included if they provided a defnition of late effects and/or presented a review of late effects as a result of adult-onset cancers in patients aged 18 years or older. Reviews related to nonmelanoma skin cancer were excluded. Reviews focusing on late effects in survivors of childhood-onset cancers (younger than 18 years) were ineligible for inclusion in the review. A total of 16 reviews were identifed. Between 0% and 100% of survivors experienced a range of physical, psychological and social late effects. The onset of physical late effects was defned broadly as 'months or years' after treatment, whereas psychological late effects were defned as occurring at the end of treatment or similarly to physical late effects as 'months or years' after treatment. Few reviews provided an operational defnition of late effects, and the onset of late effects was not often reported. Thus, reviews may have included the acute and long-term effects of cancer treatment. Evidence regarding causes, prevalence, and onset was incomplete for many late effects. Understanding the cause and onset of late effects is important in order to provide timely interventions to reduce the risk of late effect development in cancer patients.
I mproving understanding about the development of late efects after treatment is becoming an increasingly important area of investigation because of the rising number of cancer survivors worldwide. [1] [2] Previously, survivors of adult cancers did not live long enough for late efects to develop because they were more likely to die from the disease or from acute treatment efects. 3 As the prospect of long-term survival for adult-onset cancers has improved greatly, there is a need to devote eforts to further understanding about late efects in this population, including addressing research on the prevalence of late efects and associated treatments. [4] [5] Understanding when late efects emerge and identifying treatments for them is important to assist cancer care professionals in generating treatment summaries and survivorship care plans for patients' after hospital recovery and follow-up care. 6 Cancer survivors with late efects experience signifcantly poorer physical and mental health, report more unmet needs for care, and have signifcantly greater use of health services compared with survivors without late efects. 7 Terefore, it is important to try to identify and assess survivors who are afected by specifc late efects and to provide data to facilitate the design and delivery of appropriate services that will meet the needs of survivors with late efects.
Tis paper provides a rapid review of relevant research to identify which late efects are experienced by survivors of adult-onset cancers, when those late efects frst appear in relation to treatment completion, how many survivors are afected by late efects, and which treatments are associated with each late efect. Examples are provided of clinically relevant assessment tools for each late efect.
Methods
We adopted a rapid review approach rather than a full systematic review because we needed to transfer relevant knowledge into service planning and practice under given time constraints. Te review was informed by 2 empirical studies of review methodology. First, a typology of reviews identifed 14 varieties of literature review. In this typology, rapid reviews were defned as an "assessment of what is already known about a policy or practice issue, by using systematic review methods to search and critically appraise existing research" (p. 95). Te completeness of searching in a rapid review is defned or delimited by time constraints and there is a timelimited formal quality assessment. Synthesis is typically narrative and tabular. Analysis addresses the quantity of studies and the overall quality and direction of the observed efect. 8 Second, a comprehensive review of the term "rapid review" suggested that Review internationally there is not yet a consensus about its meaning or how it difers from a systematic review. 9 Key features appear to be restricted research questions and truncated search strategies and an argument that the transparency of the methods used for each review is more important than the development of a formalised methodology by which to conduct rapid reviews.
An initial scoping exercise of bibliographical databases (eg, MEDLINE and CINAHL) identifed more than 10, 000 primary studies that were relevant to late efects as a result of treatment for adult cancers. Te scope identifed a number of existing reviews, including relatively recent reviews. Terefore, we decided to conduct a rapid review of reviews. We used Google Scholar to identify reviews about the diferent late efects that may occur after treatment for cancers, including how they were defned and measured. Google Scholar is a large search engine that contains a range of published, peer-reviewed academic papers. Abstracts and papers from large bibliographic databases such as PUBMED and MEDLINE are uploaded regularly onto Google Scholar. Te search engine uses a ranking algorithm that takes into account the full text, author, citation counts, key terms, and source of publication, so that the most relevant papers tend to be ranked frst. 10 We used search terms including adult cancer, late efects and review to identify relevant papers between 1980 and July 2012. Reviews that synthesised primary studies (about defnition, causes, onset, and prevalence) on late efects (including social and psychological efects as well as physical health efects) which developed after treatment for cancers diagnosed during adulthood (18 years or older) were included in the rapid review. Mixed reviews of studies of late efects in childhood (younger than 18 years) and adult cancer survivors were included if the review provided a separate analysis and discussion section for adult survivors. In all, 10,800 papers were identifed by Google Scholar, and we searched the frst 20 pages (200 papers) of the results for relevant reviews. We decided to use data from the frst 20 pages given the nature of Google Scholar's ranking algorithm and the absence of additional relevant reviews in later pages. From this search, we identifed 12 reviews and another 5 were identifed from the subsequent reference lists. Te reviews were supplemented by referring to primary empirical studies when we needed clarifcation. Data regarding the defnition, causes, onset, and prevalence of late efects were extracted from each review using a standardised pro forma. A narrative synthesis of the results is presented in Tables 1-4 .
Results
Only 3 reviews provided defnitions of late efects. Te other 15 reviews did not conceptualise late efects in any explicit way. Two of the defnitions included physical problems (eg, pain) and psychological problems (eg, fear of recurrence). 5, 11 One review focused on physical efects only. 3 Each review defned the onset of physical late efects as occurring during an undefned period, "months or years after treatment" completion. 3, 5, 11 Stein and colleagues 5 differentiated between the onset of psychological late efects and physical late efects (but without providing any evidence or explanation to support their approach). Te onset of psychological late efects emerged from around the end of treatment onwards 5 whereas the second review defned the onset of psychological late efects as occurring "some time" after treatment similar to physical late efects. 11 Te lack of precision regarding the onset of late efects may be a result of individual variation between survivors (eg, the increased risk of treatment-induced menopause in women who receive treatment after the age of 30 years) or to individual diferences between the natural course followed by late efects, or to other factors. Te impact of late efects was characterised as a long-term change in health status and/or health-related quality of life.
11 Tis conceptualisation of late efects as involving change may suggest that they were not present before the cancer experience or that they were not experienced to the extent to which they were experienced after cancer treatment. Te duration of late efects tended to be couched in terms of being long-lasting, though the period of time was not defned. 11 Te extent to which late efects are chronic, long-lasting, or dissipate after a period of time has not been empirically assessed, and there appears to be a lack of precision about the onset of late efects.
Physical late efects
Secondary malignancies. Secondary malignancies tend to develop years after cancer treatment and include solid tumors and hematological cancers across a number of cancer sites. 1, 3, [11] [12] [13] [14] Te causes of secondary malignancies have been attributed to the carcinogenic properties of chemotherapy and radiotherapy, environmental factors, genetic predisposition, lifestyle factors, or a combination of those factors. Secondary leukemia emerges within 10 years of treatment, whereas secondary solid tumors emerge 10 years or more after treatment. [11] [12] [13] A review of the epidemiology of secondary cancers showed that just under one-ffth of new-incidence cancers recorded in the SEER programme are secondary cancers. 13 Lymphoma survivors treated with radiotherapy or chemotherapy are at an increased risk of developing secondary leukemia or solid tumors, particularly an increased risk of breast cancer 10 or more years after radiotherapy. [11] [12] [13] One review highlighted a dose-response relationship for the risk of developing leukemia as a secondary cancer after receipt of alkylating or platinum-based chemotherapeutic agents to treat ovarian and testicular cancers. 13 Table 2 presents data about the prevalence, onset of late efects and any associated treatments. Secondary cancers tend to be identifed during routine cancer surveillance.
Cognitive and neurological. Cognitive impairment may occur as a consequence of radiotherapy and chemotherapy. 1, 15 Cranial radiation for brain tumors can cause necrosis and atrophy of the brain, leading to impairment in normal cognitive, visual, and auditory functioning.
14 Chemotherapy-induced cognitive problems have also been documented in survivors of breast, ovarian, prostate, smallcell lung cancer, and lymphoma. 1, 3, 5, [14] [15] [16] [17] Brain atrophy and necrosis have been reported in survivors of brain tumors. However, it is difcult to disentangle the extent to which these efects may be attributed to treatment or to the tumor itself.
14 Prevalence rates for cognitive decline as high as 48% and 61% have been reported for prostate cancer and breast cancer survivors, respectively. 17 It is important that the interpretation of fndings from these studies take into account the potential for other factors to confound cognitive functioning in cancer survivors such as stress and anxiety levels (eg, at follow-up appointments) and previous cognitive impairment that may be afected by cancer therapy receipt. 18 Neurological late efects include radiotherapy-induced brachial plexopathy in breast cancer survivors, and chemotherapy-induced peripheral sensory neuropathy and tinnitus in 2%-25% of testicular and up to 92% of ovarian cancer survivors. 1, 11, 14, 15 In addition to brain imaging techniques, obtaining a patient history and conducting neuropsychological tests help to detect the presence of cancer treatment-induced cognitive impairment. Endocrine. Cancer therapies may afect the thyroid, pituitary, or adrenal glands; the hypothalamus; or the pancreas, which could result in metabolic disorders. 19 In particular, hypothyroidism may result from radiation, radiation combined with chemotherapy, or hematopoietic stem-cell transplantation to treat head and neck cancers or after total body radiation in lymphoma survivors. 1, 11, 13 Te mechanisms by which radiotherapy causes hypothyroidism may occur directly through the vascular system or indirectly through the immune system. Hypothyroidism emerges at least 5 years or more after treatment, and incidence rates vary between 7% and 85%, depending on the diagnostic criteria and the treatment history of the survivor. 11, 19 Disorders of the endocrine system can be detected by the presence of excessive or defcient levels of hormones (eg, thyroid stimulating hormone) in blood and urine tests. Cardiopulmonary. Cardiovascular efects have been experienced by head and neck cancer, breast cancer, testicular cancer, acute myeloid leukemia, and lymphoma survivors. 1, 14, 20 Te development of cardiovascular disorders can occur between 5 and 20 years after treatment, and mortality from cardiovascular late efects can occur after 10 years. 14, 20 Chemotherapy and chemotherapy-radiation combined regimens have been associated with cardiovascular disorders because of the generation of free radicals. 1, 14, 20 Incidence rates of radiotherapy-induced cardiovascular toxicity have been reported in 10%-30% of survivors, and the toxicities have emerged within 10 years of treatment completion. 20 Pulmonary late efects include radiation pneumonitis, pulmonary fbrosis, idiopathic pneumonia syndrome, and generally impaired pulmonary function induced by chemotherapy, radiotherapy, and stem-cell transplantation. 1, 14, 20 A thorough cardiac and pulmonary assessment, including imaging, will help to identify cardiopulmonary late efects. Chemotherapeutic agents such as cisplatin, methotrexate, and nitrosoureas have led to impaired renal function and in some cases patients have required dialysis. 1, 11 Renal late efects can be detected with blood and urine tests, as well as imaging of the kidneys. Fertility and sexual dysfunction. A signifcant late efect -particularly for survivors of childbearing age or of hematological or reproductive organ cancer -is a loss of fertility because of gonadal failure, including treatmentinduced menopause. 1, 12, [14] [15] 19, 21 Te prevalence of gonadal failure in survivors of Hodgkin lymphoma is reported to be between 15% and 35%. 12 Up to 63%, 47%, and 32% of ovarian, testicular, and brain cancer survivors, respectively, experience gonadal failure. 19 Prostate cancer survivors and survivors from other cancer sites also experience gonadal failure. 1, 3, 14 Treatment-induced infertility has been associated with chemotherapy and radiotherapy to the abdomen. Late effects refer specifcally to unrecognised toxicities that are absent or subclinical at the end of therapy and manifest months or years later, due to the identifcation of previously unseen injury, organ senescence and the failure of compensatory mechanisms.
Tichelli 11
Late effects are long-term changes in the health status of a cancer survivor that are often absent immediately after cancer treatment and may produce physical or psychological morbidity. Late effects also have an impact on the survivor's relationships (eg, graft versus host disease).
Stein 5
General Problems that are not present or identifed after treatment but may develop as outgrowths of the effects on organ systems or the psychological process. These effects have a negative impact on the quality of life of a cancer survivor (eg, cardiopulmonary dysfunction).
Specifc -psychological Psychological or emotional responses that emerge at the end of treatment completion and may include positive effects (eg, anxiety). Review Premature-onset menopause in women who survive cancer is associated particularly with alkylating chemotherapeutic drug receipt. 12 Between 21% and 100% of survivors (including gynecologic cancer survivors who have been treated with surgery) experience treatment-induced menopause. 1, 3, 5, 12, [14] [15] 19 Te risk of treatment-induced menopause or amenorrhea increases if women are treated for cancer when they are older than 30 years. Many female cancer survivors who experience early-onset menopause lose the protective efects of estrogen against heart disease and osteoporosis that can be counteracted with the use of hormone therapies. 1 However, there may be an increased risk of cancer recurrence with the use of hormone therapies. 12 Sexual dysfunction in the form of loss of libido, pain with sexual activity, or erectile dysfunction can be experienced by many cancer survivors (Table 2) . Between 5% and 85% of cancer survivors of the reproductive organs including gynecologic, prostate and testicular survivors experience sexual dysfunction. 5, [14] [15] 17, 21, 22 Sexual dysfunction is experienced by survivors of breast (57%), colorectal (77%), lymphoma (50%), brain (47%) and other (61%) cancers. 3, 5, 12, 15, 17, 19, 21 Sexual late efects can occur as a result of damage to the physiological systems involved in sexual functioning as a consequence of surgery, radiotherapy and chemotherapy treatment, but may also be attributed to intra-individual psychological changes. 5, 21 See Table 2 for clinically relevant tools and tests that assess fertility-related problems and sexual late efects. 3, 23 Urinary and bowel. Treatment for bladder cancer may result in up to 70% of cancer survivors experiencing urinary leakage.
Review
14 Urinary problems such as blockage or incontinence have been experienced by men who have been treated for prostate cancer. 5, 15 After radical prostatectomy, up to 50% of prostate cancer survivors may experience urinary leakage.
14 Urinary problems have also been reported in survivors of ovarian cancer. 15 Between 6% and 8% of cervical and colorectal cancer survivors experience urinary late efects.
14 Urinary dysfunction is assessed using a clinical interview and renal assessment. Bowel disorders have also been documented in prostate and ovarian cancer survivors.
5,14-15 Between 10% and 20% of colorectal, prostate, and cervical cancer survivors experience bowel-related late efects after treatment. 14, 24 Musculoskeletal disorders. One review reported that musculoskeletal late efects are the most common physical late 
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efects experienced by cancer survivors, including pain and impairments in physical functioning. 5 Pain has been reported in lymphoma and testicular survivors, up to 27% of colorectal, up to 70% of prostate, and up to 70% of breast cancer survivors after treatment. 5,15,17,22, 24--25 Signifcant predictors of pain include radiotherapy and younger age at treatment. 15 Pain may be assessed using patient-reported outcome measures such as the Brief Pain Inventory and the McGill's Pain Questionnaire. 26, 27 Radiotherapy has been attributed directly to muscle atrophy, osteonecrosis, and increased risk of fractures. Te development of osteoporosis after treatment has been associated with receipt of radiotherapy and steroids, whereas the development of osteonecrosis is associated with chemotherapy, radiotherapy, and steroid receipt. 11, 14 Chronic pain, which is experienced by a high number of cancer survivors, may be attributed to scarring of the tissue surrounding joints or peripheral nerves.
1
Other physical late effects. Impaired immune functioning such as an increase in infectious diseases may result from removal of the spleen. Tis has been documented in Hodgkin lymphoma survivors. 1, 14 Immune system impairment may be experienced as a direct result of the disease in this survivor group. 1 Fatigue can be a debilitating, longlasting efect for cancer survivors after treatment. Up to 56% of breast, 33% of gynecologic, 50% of colorectal, 60% of prostate, and 33% of lymphoma survivors may experience fatigue after treatment. 12, [14] [15] 17, 24 Te exact etiology of fatigue after treatment is unknown.
14 However, fatigue is often experienced before or during treatment. As a result, this may be a long-lasting efect rather than an efect with a delay before presentation after treatment (ie, a late efect). 15 Fatigue may be assessed by patient-reported outcome measures, clinical interview and an assessment of thyroid gland functioning. 3, 30 Damage to lymph nodes following curative surgery has led to edema. 5 Lymphedema is particularly prevalent in the upper limbs of breast cancer survivors and the lower limbs of gynecologic cancer survivors. Table 3 presents data on the prevalence, onset of late efects, and the associated treatments. Examples of patientreported outcome measures that may be used in clinical settings to identify psychological late efects in cancer survivors are provided in the Table 3 .
15,25,28-29

Psychological late efects
Psychological distress (generalised and specifc). Psychological distress incorporating cancer-related worries, anxiety, and depression has been experienced by survivors of cancers from various sites. 5, 22, [31] [32] For example, high levels of distress were reported by up to 31% of head and neck cancer survivors who had been treated with radiotherapy, in 17%-19% of breast cancer survivors, 36%-44% of prostate cancer survivors, 26%-41% of cancer survivors from a number of sites, and an unspecifed number of lymphoma survivors. 22, [31] [32] Te psychological distress experienced by cancer survivors may be more specifc, such as distress related to attendance for follow-up tests. Fear of recurrence is a common and persistent efect experienced by many survivors. 1, 5, 24, 31 Research aimed at measuring or understanding fear of recurrence is limited. 4 Other anxiety-related efects include fear of disease progression, sleep disturbances, psychosexual problems, fertility concerns, and body image concerns. 1, 5, 12, [15] [16] [17] 22, 24 Distress can be measured using patientreported outcome measures and screening tools. [33] [34] [35] [36] [37] [38] [39] [40] [41] Depression and anxiety. Studies have documented that up to 58% and 48% of survivors from a number of cancer sites have nonclinical depressive and anxiety symptoms, respectively. 5, 17, 22, 25 Variation in reporting of depressed mood and anxiety may be due to variation relating to cancer site, measurement, and other factors. Similar to the general population, female cancer survivors were more likely to experience depressive symptoms than were their male counterparts. 31 Clinical depression occurs less frequently in the cancer survivor population than does depressive mood, while up to 31% of gynecologic, lung, colorectal, and prostate cancer survivors, are assessed as being clinically depressed. 17, 31 None of the reviews reported the prevalence of clinical anxiety disorders in cancer survivors. However, individual studies have reported a prevalence rate of 12% for clinical anxiety and of 31% for subclinical anxiety by survivors of various cancer sites, including gynecologic, testicular, and lymphoma. 42 Depression and anxiety (including many anxiety-related efects) may be measured by patient-reported outcome measures and a clinical interview based on the Diagnostic Criteria Manual (DSM) for Mental Disorders criteria. 43 Posttraumatic stress disorder. Te diagnosis of a life-threatening illness such as cancer has been added to the DSM since its fourth revision in 2000. 44 Between 0% and 32% of breast, head, and neck, and other cancer survivors have experienced PTSD. 5, 31 Recent research has suggested that head and neck and hematological cancer survivors are more vulnerable to PTSD, although explanatory mechanisms for this vulnerability are not known. 5 PTSD may be identifed by using a specifc scale (eg, Post-Traumatic Diagnostic Scale) or through clinical interview using the DSM criteria.
45
Posttraumatic growth. Receiving a cancer diagnosis and subsequent treatment can be a traumatic event for many patients and lead to negative psychological efects in survivors and their families, positive efects such as posttraumatic growth (PTG) have also been reported. PTG involves an intra-individual spiritual change and is characterised by improvements in relationships, a positive change in a survivor's outlook toward life and empathy toward others. [46] [47] Tis positive late efect of the cancer experience was reported by 3 reviews. 5, 12, 46 Factors that may play a role in the development of positive PTG-like efects (as opposed to negative efects) from cancer include social support, information seeking behaviors and complementary and alternative therapy use. 48 Tese factors may act as potential modifable factors that may be useful for the development of interventions targeted at cancer survivors. PTG may be measured using the Post-Traumatic Growth Inventory (PTGI).
Review
46
Social late efects
Cancer survivors may experience social efects relating to their cancer experience such as changes in relationships, and/or employment-and fnance-related changes. Relationships in families, between intimate partners and social contacts may change in positive and negative ways. 1, 12, 31 Previous literature has found that cancer survivors are more likely than the general population to be unemployed. 16 Further employment-related efects experienced by cancer survivors include difculty reintegrating into work life, job lock, discrimination, fear of losing benefts, and disease-associated stigma. 1, 12, 15, 31 Cancer and cancer treatment may also lead to fnance-related issues such as difculty obtaining medical or travel insurance and securing credit, including mortgages and paying bills such as child care. 1, 12, 31 Tere do not seem to be any clinically relevant assessment tools to identify social problems after cancer diagnosis and treatment, but the Impact of Cancer Scale may be a useful tool for clinicians. 49 
Discussion
We included 17 reviews in our rapid review. We found wide variation in the reporting of late efects, which might have been the result of diferences in defnitions and assessment methods. For example, depression measured as a mood or a clinical disorder provided diferent prevalence rates. 17 Te fndings of this review suggest that as many as 100% of cancer survivors experience late efects. Up to 100% of ovarian cancer survivors (younger than 40 years) who had been treated with combination cytotoxic drugs experienced treatment-induced menopause. 19 Te most prevalent late efects aside from treatment-induced menopause include peripheral sensory neuropathy (up to 92%), hypothyroidism (up to 85%), sexual dysfunction (up to 77%), urinary Review disorders (up to 70%), and pain (up to 70%). Although some of these late efects (eg, peripheral sensory neuropathy and hypothyroidism) are limited to a few cancer sites, psychological and social late efects or physical late efects such as sexual dysfunction, pain or fatigue are experienced by survivors from many diferent cancer sites.
Physical late efects afecting each major organ system were found. Physical late efects as a result of cancer treatments have been studied more extensively than have other types of late efects. However, there are gaps that need to be addressed. None of the reviews reported the onset of neurotoxic, neurological, endocrine (with the exception of hypothyroidism), pulmonary, hepatic, urinary, reproductive, musculoskeletal, gastrointestinal, or other late efects (eg, fatigue and lymphedema). Many treatments associated with the onset of physical late efects have been identifed. However, the particular cancer treatments and etiological pathway involved in the development of fatigue remains unknown. Furthermore, the numbers of cancer survivors who develop neurotoxic late efects, brachial plexopathy, endocrine efects (with the exception of hypothyroidism), chemotherapy-induced cardiac efects, pulmonary efects, liver and kidney efects, osteoporosis, and lymphedema were not identifed by the rapid review. Limited information regarding prevalence of late efects may be explained by the broad scope of many of the included reviews giving an overview of many late efects across a number of cancer sites. Aside from traditional clinical assessments to identify many physical late efects, patient-reported outcome measures are also available for physical efects such as sexual dysfunction, pain and fatigue, which may be useful in a clinical setting. In addition, there is a need to give empirical research attention to the onset, prevalence and causes of psychological late efects, particularly anxiety-related efects such as body image concerns, fertility concerns, and fear of recurrence. Although it is likely that psychological late efects are caused by the experience of being diagnosed with, treated for, and recovering from cancer rather than occurring as a direct result of treatments, they may also occur as a result of physical late efects (eg, depression as a result of treatment-induced pain). Tere are symptom-or disease-specifc measures available for psychological late efects.
Social efects may occur as a result of the general cancer experience or after the impact of specifc physical or psychological late efects (eg, the experience of lymphedema or depression), which may impact on capacity to work and thus the fnancial situation of cancer survivors. None of the included reviews provided fndings regarding the number of survivors who experience cancer-related social efects and there is a need for further investigation.
Tere is extensive knowledge regarding late efects after childhood cancers. Identifying and understanding late efects in survivors of adult-onset cancers is more complex because of aging processes and comorbidities. 5, 14 Generally, factors associated with the development of late efects in adult-onset survivors include a patient's lifestyle, age at treatment receipt and, as identifed by the rapid review some late efects, are associated with particular treatments. 5 Moreover, there is an increased risk of late efect development when more than one treatment has been received and survivors are at risk of late efects associated with each treatment. 5, 7 In addition to the specifc tools identifed in the rapid review, there are a few clinically relevant generic tools that may help health care professionals to identify late efects in their patients. Te Common Terminology Criteria for Adverse Events (CTCAE) is a clinician-administered scale and measures the presence and severity of long-term and late efects. However, it is lengthy and time intensive to complete. 50 51 Both tools assess physical efects only. Te UK National Cancer Survivorship Initiative has developed a Concerns Checklist that may be used as a screening tool for psychological and social late efects. 52 It is important to note that this review was not conducted using a systematic search strategy though a structured and focused approach was used to identify relevant existing reviews. Also, the results of the rapid review were supplemented by results from the individual primary papers included in the reviews. Tere is a possibility that the rapid review of reviews may not have identifed some late efects or treatments associated with the development of late efects. For example, specifc social late efects such as bankruptcy and poverty were not identifed. 53 Tere was limited coverage of studies of the development of efects in breast and prostate cancer survivors relating to the strong association between hormone replacement therapy and endocrine therapy. Many cancer survivors receive hormone therapy as adjuvant treatment to reduce their risk of cancer progression and they may receive this treatment for many years. Side-efects may occur during the course of receiving the therapy, whereas late efects emerge a period of time after treatment has been completed. [54] [55] Many of the primary studies in the reviews were cross-sectional in nature; longitudinal cohort studies would be a more appropriate study design to collect onset data about late efects. 5, 17 Nevertheless, the rapid review successfully collated and narrated information about late efects in a pragmatic way as well as identifying research gaps.
Te rapid review is an easily accessible and quick guide for clinicians and others about specifc sites and specifc treatments associated with late efects. It also provides examples of clinically relevant tools to identify efects in cancer patients. It was impossible within the scope of this review to identify every clinically relevant tool for assessing each late efect within each cancer site. Uncovering which treatment or intervention was the most efective for each late efect would require separate systematic reviews akin to Cochrane Collaboration reviews. Moreover, there are many diferent types of treatments or interventions that may ameliorate cancer late efects. For example, a number of Cochrane Collaboration reviews that address the efectiveness of exercise interventions, 56 psychosocial interventions, 57 pharmacological therapies, 58 and education interventions 59 to manage cancer-related fatigue have been identifed. Web-based resources such as the US-based National Cancer Institute provide practical support for patients and clinicians regarding many late efects identifed in this rapid review. 60 Many of the papers included in the rapid review neglected to provide a defnition of late efects. Late efects were defned in terms of their onset and were thus diferentiated from other types of efects such as acute, shortterm efects, and long-lasting efects that present during or prior to treatment. Tis review provides clarity regarding how late efects are defned and it identifed commonalities regarding the onset of physical late efects as occurring "months or years" after treatment as well as pointing out that there was less agreement regarding the onset of psychological late efects. Many of the reviews did not report the onset of late efects and more research is needed to understand when psychological, social, and many physical late efects frst present after cancer treatment. It is important that clinicians are aware when efects frst emerge so that timely identifcation and intervention can be provided. For example, hypothyroidism has been identifed as emerging 5 years after cranial radiation for cancers of the head and neck. Screening patients with this cancer and treatment history will help clinicians provide appropriate care and treatment at the right time.
Research is constantly contributing to the development of better, more efcacious treatment that will contribute to the achievement of optimum survival rates, by taking into account the impact of cancer treatment on the long-term morbidity and quality of life of survivors. Future research should address the gaps identifed by this review and use the existing knowledge to develop interventions and strategies that reduce the risk, or prevent the development, of late efects in cancer patients and survivors.
